I'm LongbridgeAI, I can summarize articles.Silo Pharma raised approximately $3.5 million in net proceeds from a private placement of common stock and warrants to institutional investors for working capital. The company also entered into a Registration Rights Agreement, requiring the filing of resale registration within 15 days and targeting effectiveness within 30 to 60 days, thereby enhancing investor liquidity.
Silo Pharma completed a private placement with institutional investors, selling common stock and issuing pre-funded and common warrants, and expects approximately $3.5 million in net proceeds for working capital and general corporate purposes. The company also entered into a Registration Rights Agreement to register the resale of the issued shares and shares underlying the pre-funded and common warrants, with filing due within 15 days and targeted effectiveness within 30 days (or 60 days if fully reviewed by the SEC). Together, the financing and resale arrangements aim to strengthen liquidity while providing investors with a path to tradability.
Agreement 1: Silo Pharma Raises Approximately $3.5 Million Net in Private Placement of Stock and Warrants
- Agreement type: Securities Purchase Agreements for private placement of equity and warrants
- Counterparty: Certain institutional investors
- Signed / Effective: Jul 09 2026 / Jul 09 2026
- Duration / Termination: At will
- Reason: Fund working capital and general corporate purposes
Agreement 2: Silo Pharma Grants Investors Resale Registration Rights Following Private Placement
- Agreement type: Registration Rights Agreement for resale of securities
- Counterparty: Purchasers in the private placement
- Signed / Effective: Jul 09 2026 / Jul 09 2026
- Duration / Termination: Until resale registration effective
- Reason: Provide resale liquidity for investors
Original SEC Filing: Silo Pharma, Inc. [ SILO ] - 8-K - Jul. 10, 2026